Kyle – No Brexit deal on regulation will devastate pharmaceutical industry

Regulatory alignment with the EU after Brexit is “critical” and failure to agree mutual recognition of standards could lead to a “nightmare scenario”, Mike Thompson, Chief Executive of the Association of the British Pharmaceutical Industry (ABPI), told the House of Commons Business, Energy and Industrial Strategy Select Committee today. 

Commenting, Peter Kyle MP, leading supporter of Open Britain and member of the Business, Energy and Industrial Strategy Select Committee, said: 

“Amid the chaos reigning today on regulatory divergence or alignment, the pharmaceutical industry is absolutely clear that failure to get a deal with Brussels on regulation will devastate the sector and put jobs and our NHS at risk. 

“The Government must keep Britain in the Single Market. Anything less could disrupt international supply chains and leave one of our country’s most successful industries on its knees. 

“Nobody voted to become worse off as a result of Brexit. The British people have a right to keep an open mind about whether this is really the best future for our country.” 


Notes to editors:

Video of the Select Committee hearing is here: